A pharma giant is moving past one patent cliff — but another is already looming

#stockmarkets #investor news #smallcaps #microcaps

Disappointing data highlights Novartis’ challenge to build its next generation of blockbuster medicines, following a series of clinical trial setbacks.

Share this article:
This article was originally published here.